{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:24:12Z","timestamp":1785507852896,"version":"3.56.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00418","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T14:54:05Z","timestamp":1597330445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade\u00ae to Remsima\u00ae? An Observational Study"],"prefix":"10.3389","volume":"7","author":[{"given":"Laixi","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"van Bilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W. J.","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E. J.","family":"van Velthoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. O.","family":"Missotten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A. H. J.","family":"Thiadens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. W. A. M.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van Biezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. A. S. H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A. W.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A.","family":"Dik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L. A.","family":"van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD005112","DOI":"10.1002\/14651858.CD005112.pub2","article-title":"Tumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitis","volume":"2006","author":"Lawson","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD003785","DOI":"10.1002\/14651858.CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","volume":"2002","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD003574","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","volume":"2004","author":"Akobeng","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4161\/mabs.25864","article-title":"Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry","volume":"5","author":"Beck","year":"2013","journal-title":"MAbs."},{"key":"B5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40259-014-0094-1","article-title":"A review of CT-P13: an infliximab biosimilar","volume":"28","author":"McKeage","year":"2014","journal-title":"BioDrugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s12325-015-0233-1","article-title":"The budget impact of biosimilar infliximab (Remsima(R)) for the treatment of autoimmune diseases in five european countries","volume":"32","author":"Jha","year":"2015","journal-title":"Adv Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40259-017-0252-3","article-title":"Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK","volume":"31","author":"Aladul","year":"2017","journal-title":"BioDrugs."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","article-title":"Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data","volume":"15","author":"Nikiphorou","year":"2015","journal-title":"Expert Opin Biol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"48","author":"Adler","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J."},{"key":"B14","first-page":"86","article-title":"Infliximab for uveitis of Behcet's syndrome: a trend for earlier initiation","volume":"35","author":"Guzelant","year":"2017","journal-title":"Clin Exp Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ddg.13741","article-title":"Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients","volume":"17","author":"Herberger","year":"2019","journal-title":"J Dtsch Dermatol Ges."},{"key":"B16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.4730020305","article-title":"The RAND 36-Item Health Survey 1.0","volume":"2","author":"Hays","year":"1993","journal-title":"Health Econ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut."},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/rheumatology\/keg453","article-title":"The Behcet's disease activity index","volume":"43","author":"Lawton","year":"2004","journal-title":"Rheumatology (Oxford)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00296-016-3593-1","article-title":"Development of an activity disease score in patients with uveitis (UVEDAI)","volume":"37","author":"Pato","year":"2017","journal-title":"Rheumatol Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/ibd\/izy227","article-title":"Drug survival and immunogenicity after switching from remicade to biosimilar CT-P13 in inflammatory bowel disease patients: two-year follow-up of a prospective observational cohort study","volume":"25","author":"Smits","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1080\/19420862.2017.1337620","article-title":"Glycosylation profile and biological activity of Remicade(R) compared with Flixabi(R) and Remsima(R)","volume":"9","author":"Lee","year":"2017","journal-title":"MAbs."},{"key":"B24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.tibtech.2018.05.002","article-title":"Infliximab biosimilars in the age of personalized medicine","volume":"36","author":"Kang","year":"2018","journal-title":"Trends Biotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest."},{"key":"B27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","article-title":"A systematic review of the off-label use of biological therapies in systemic autoimmune diseases","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/imj.14215","article-title":"The use of biologic agents in the management of uveitis","volume":"49","author":"Trivedi","year":"2018","journal-title":"Intern Med J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T14:54:10Z","timestamp":1597330450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":31,"alternative-id":["10.3389\/fmed.2020.00418"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00418","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"article-number":"418"}}